Evidence map›Paper›PMID 28921647›Full record

ReviewJournal of clinical pharmacology2017

Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

Tristan M Sissung, Jon W McKeeby, Jharana Patel, Juan J Lertora, Parag Kumar, Willy A Flegel, Sharon D Adams, Ellen J Eckes, Frank Mickey, Teri M Plona and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. UGT1A1 Fragment Analysis: Genotyping the (TA)Journal of clinical laboratory analysis · 2026
    Article
  4. Review
  5. Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.Annual review of genomics and human genetics · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)International journal of molecular sciences · 2020
    Article
  10. Observational
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tristan M SissungClinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Rockville, MD, USA.
Jon W McKeebyDepartment of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA.
Jharana PatelPharmacy Department, NIH Clinical Center, Bethesda, MD, USA.
Juan J LertoraClinical Pharmacology Program (2006-2016), NIH Clinical Center, Bethesda, MD, USA.
Parag KumarClinical Pharmacokinetics Research Laboratory, NIH Clinical Center, Bethesda, MD, USA.
Willy A FlegelDepartment of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA.
Sharon D AdamsDepartment of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA.
Ellen J EckesMedical Surgical Specialties Service, Clinical Center Nursing Department, NIH, Bethesda, MD, USA.
Frank MickeyDepartment of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA.
Teri M PlonaCLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Stephanie D MellotCLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Ryan N BaugherCLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Xiaolin WuGenomics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Daniel R SoppetGenomics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Mary E BarcusCLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Vivekananda DattaCLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Kristen M PikeCLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Gary DiPatrizioDepartment of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA.
William D FiggClinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Rockville, MD, USA.
Barry R GoldspielPharmacy Department, NIH Clinical Center, Bethesda, MD, USA.

Funding

Clinical PharmacogeneticsZIABC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$13.9M
Intramural NIH HHS ZIA BC010627
6 · The paper itself

Abstract

The National Institutes of Health Clinical Center (NIH CC) is the largest hospital in the United States devoted entirely to clinical research, with a highly diverse spectrum of patients. Patient safety and clinical quality are major goals of the hospital, and therapy is often complicated by multiple cotherapies and comorbidities. To this end, we implemented a pharmacogenomics program in 2 phases. In the first phase, we implemented genotyping for HLA-A and HLA-B gene variations with clinical decision support (CDS) for abacavir, carbamazepine, and allopurinol. In the second phase, we implemented genotyping for drug-metabolizing enzymes and transporters: SLCO1B1 for CDS of simvastatin and TPMT for CDS of mercaptopurine, azathioprine, and thioguanine. The purpose of this review is to describe the implementation process, which involves clinical, laboratory, informatics, and policy decisions pertinent to the NIH CC.

Indexed as

Biomedical ResearchDecision Support Systems, ClinicalGenotypeHumansMedical InformaticsNational Institutes of Health (U.S.)Organizational PolicyPharmacogeneticsUnited Statesimplementationpharmacogenomicsprecision medicinetranslation

Identifiers

PMID28921647
PMCPMC5657584

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.